BACKGROUND AND OBJECTIVE: There are currently no sensitive and specific assays for activin B that could be utilized to study human biological fluids. The aim of this project was to develop and validate a 'total' activin B ELISA for use with human biological fluids and establish concentrations of activin B in the circulation and fluids from the reproductive organs. DESIGN: The new ELISA was validated and then used to measure activin B levels in the circulation of healthy participants, IVF patients, pregnant women and in ovarian follicular fluid and seminal plasma. PATIENTS AND MEASUREMENTS: Healthy adult subjects (n = 143), subjects from an IVF clinic (n = 27) and pregnancy groups (n = 29) were sampled. RESULTS: The sensitivity of the assay was 0.019 ng/ml. Validation of the activin B ELISA showed good recovery (90.7 +/- 9.8%) and linearity in biological fluid and cell culture media and low cross-reactivity with related analytes (inhibin B = 0.077% and activin A = 0.0034%). There was a negative correlation between activin B concentration (r = -0.281, P < 0.011) and females with increasing age. Patients attending IVF clinics had significantly lower levels of activin B compared with gender-matched control subjects. Ovarian follicular fluid and seminal plasma had 50-80 fold higher levels of activin B (mean = 5.35 and 3.66 ng/ml respectively) than sera (mean = 0.071 ng/ml). CONCLUSIONS: This fully validated ELISA for activin B offers a tremendous utility for measuring this protein in a variety of normal physiological processes and in various clinical pathologies.
BACKGROUND AND OBJECTIVE: There are currently no sensitive and specific assays for activin B that could be utilized to study human biological fluids. The aim of this project was to develop and validate a 'total' activin B ELISA for use with human biological fluids and establish concentrations of activin B in the circulation and fluids from the reproductive organs. DESIGN: The new ELISA was validated and then used to measure activin B levels in the circulation of healthy participants, IVFpatients, pregnant women and in ovarian follicular fluid and seminal plasma. PATIENTS AND MEASUREMENTS: Healthy adult subjects (n = 143), subjects from an IVF clinic (n = 27) and pregnancy groups (n = 29) were sampled. RESULTS: The sensitivity of the assay was 0.019 ng/ml. Validation of the activin B ELISA showed good recovery (90.7 +/- 9.8%) and linearity in biological fluid and cell culture media and low cross-reactivity with related analytes (inhibin B = 0.077% and activin A = 0.0034%). There was a negative correlation between activin B concentration (r = -0.281, P < 0.011) and females with increasing age. Patients attending IVF clinics had significantly lower levels of activin B compared with gender-matched control subjects. Ovarian follicular fluid and seminal plasma had 50-80 fold higher levels of activin B (mean = 5.35 and 3.66 ng/ml respectively) than sera (mean = 0.071 ng/ml). CONCLUSIONS: This fully validated ELISA for activin B offers a tremendous utility for measuring this protein in a variety of normal physiological processes and in various clinical pathologies.
Authors: Tejinder P Sharma; Terry M Nett; Fred J Karsch; David J Phillips; James S Lee; Carol Herkimer; Vasantha Padmanabhan Journal: Biol Reprod Date: 2012-06-07 Impact factor: 4.285
Authors: David Morritz de Kretser; Jonathan Guy Bensley; Ville Pettilä; Rita Linko; Mark Peter Hedger; Susan Hayward; Carolyn Anne Allan; Robert Ian McLachlan; Helen Ludlow; David James Phillips Journal: Crit Care Date: 2013-10-31 Impact factor: 9.097
Authors: Helen B Forrester; Peter Temple-Smith; Seungmin Ham; David de Kretser; Graeme Southwick; Carl N Sprung Journal: PLoS One Date: 2013-03-12 Impact factor: 3.240
Authors: Rita Linko; Mark P Hedger; Ville Pettilä; Esko Ruokonen; Tero Ala-Kokko; Helen Ludlow; David M de Kretser Journal: BMC Infect Dis Date: 2014-05-10 Impact factor: 3.090
Authors: David M de Kretser; Jonathan G Bensley; David J Phillips; Bronwyn J Levvey; Greg I Snell; Enjarn Lin; Mark P Hedger; Robyn E O'Hehir Journal: PLoS One Date: 2016-01-28 Impact factor: 3.240
Authors: Natasha Spottiswoode; Andrew E Armitage; Andrew R Williams; Alex J Fyfe; Sumi Biswas; Susanne H Hodgson; David Llewellyn; Prateek Choudhary; Simon J Draper; Patrick E Duffy; Hal Drakesmith Journal: Infect Immun Date: 2017-11-17 Impact factor: 3.441